



## AN OBSERVATIONAL STUDY OF CHANGES IN BONE HOMEOSTASIS IN PATIENTS UNDERGOING LONG-TERM DIALYSIS IN A TERTIARY CARE HOSPITAL IN KOLKATA

### Orthopedics

**Dr. Sandipan  
Bhattacharya**

MS Orthopedics Senior Resident Department of Orthopaedics Vivekananda Institute of Medical Sciences

**Dr Arnab paul\***

MS Orthopedics Senior Resident Department of Orthopaedics Vivekananda Institute of Medical Sciences \*Corresponding Author

**Dr. Prasanta  
Kumar Pujari**

Professor & Head, Department of Orthopaedics Ramakrishna Mission Seva Pratishthan

**Dr. Bikramjit  
Gayen**

Assistant Professor, Department of Orthopaedics Ramakrishna Mission Seva Pratishthan

### ABSTRACT

**Background:** Chronic kidney disease–mineral bone disorder (CKD-MBD) significantly alters bone homeostasis in patients on long-term dialysis. This study aimed to evaluate changes in bone mineral density (BMD) and biochemical bone markers over time. **Methods:** A longitudinal observational study was conducted on 100 adult patients undergoing maintenance hemodialysis for more than three months. Baseline and 6-month assessments included serum calcium, phosphate, alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), vitamin D, albumin, and femoral neck BMD using DEXA. **Results:** Seventeen percent had osteoporosis (Z score  $\leq$  -2.5), and 49% had osteopenia. Age and female sex were significantly associated with low BMD ( $p < 0.001$ ). iPTH, ALP, and vitamin D levels showed significant correlation with Z scores. **Conclusion:** Long-term dialysis patients demonstrate significant alterations in bone homeostasis, particularly involving PTH and vitamin D, necessitating regular monitoring.

### KEYWORDS

#### INTRODUCTION

Chronic kidney disease (CKD) affects nearly 10% of the global population and is frequently complicated by CKD–mineral bone disorder (CKD-MBD). Impaired renal function disrupts calcium–phosphate balance, reduces vitamin D activation, and stimulates secondary hyperparathyroidism. These disturbances result in renal osteodystrophy, characterized by altered bone turnover, reduced bone mineral density (BMD), and increased fracture risk. Patients undergoing long-term hemodialysis represent a particularly vulnerable group. Persistent hyperphosphatemia, hypocalcemia, elevated iPTH levels, inflammation, and nutritional deficiencies collectively impair bone homeostasis. Although dialysis sustains life in end-stage renal disease (ESRD), it cannot fully correct metabolic derangements affecting bone integrity.

Despite therapeutic advances, CKD-MBD remains inadequately studied in long-term dialysis populations in Eastern India. This study evaluates dynamic changes in bone biomarkers and BMD in such patients.

#### Method Study Design

Longitudinal observational study conducted over 12 months. Study Population 100 adult CKD patients (18–80 years) on maintenance hemodialysis for >3 months. Inclusion Criteria Adult CKD patients on long-term hemodialysis Exclusion Criteria Dialysis <3 months Renal transplant recipients Age <18 or >80 years Patients who expired or discontinued within 1 year Data Collection Baseline and 6-month assessments included: Serum calcium Serum phosphate ALP iPTH

Vitamin D Albumin Creatinine

BMD (DEXA scan at femoral neck) Statistical Analysis

Data analyzed using SPSS v25.

Chi-square/Fisher's exact test for categorical variables Mann–Whitney U/Kruskal–Wallis test for continuous variables Spearman correlation for associations  $p < 0.05$  considered significant

#### Results Demographics

72% patients were >50 years

59% males, 41% females Bone Mineral Density Osteoporosis (Z  $\leq$  -2.5): 17%

Osteopenia (-2.5 to -1): 49%

Normal (> -1): 34% Age ( $p = 0.001$ ) and female sex ( $p < 0.001$ ) were

significantly associated with lower BMD.

Biochemical Markers iPTH:

Significantly higher in osteoporotic patients ( $p < 0.001$ ).

Mean increase over 6 months noted but change not statistically significant between groups. Vitamin D:

Significantly lower in severe osteoporosis ( $p < 0.001$ ). Baseline and 6-month differences significant across groups. ALP:

Higher baseline ALP in severe osteoporosis ( $p = 0.011$ ). Calcium & Phosphate:

No significant intergroup differences. Albumin:

Higher levels observed in patients receiving nutritional supplementation ( $p < 0.001$ ). Comorbidities

Hypertension (44%) was most common. Multiple comorbidities were more frequent in lower BMD groups.

#### DISCUSSION

This study demonstrates a high prevalence of osteopenia and osteoporosis among long-term dialysis patients. Age showed a significant inverse correlation with Z score, confirming aging as a major determinant of bone loss.

Elevated iPTH levels were strongly associated with lower BMD, indicating high-turnover bone disease as a key mechanism. Increased ALP further supported enhanced bone turnover in osteoporotic patients.

Vitamin D deficiency was significantly linked to poor bone density, highlighting its central role in mineral homeostasis. Interestingly, short-term fluctuations in calcium and phosphate did not significantly correlate with BMD, suggesting chronic hormonal dysregulation plays a greater role than transient biochemical changes.

Nutritional supplementation improved albumin and vitamin D levels, reinforcing the importance of nutritional optimization in CKD-MBD management.

Overall, bone homeostasis disruption in dialysis patients appears multifactorial, involving hormonal imbalance, nutritional deficiency, and metabolic dysregulation.

**CONCLUSION**

Long-term hemodialysis patients exhibit significant alterations in bone homeostasis, with high prevalence of osteopenia and osteoporosis.

Age, female sex, elevated iPTH, high ALP, and low vitamin D levels are strongly associated with reduced bone mineral density.

Routine monitoring of bone biomarkers and early nutritional intervention are essential to prevent fractures and improve quality of life in CKD-MBD patients.

Further long-term multicentric studies are recommended to refine management protocols.

**REFERENCES (Key references from thesis)**

1. Varma PP et al. Prevalence of CKD in Indian population. KDIGO 2009 Clinical Practice Guidelines for CKD-MBD. Khan et al., 2016 – Bone density in hemodialysis patients.
2. Gutiérrez et al., 2015 – Dialysis modality and bone metabolism. Kovesdy CP et al., 2013 – Mineral metabolism and fracture risk. Thadhani R et al., 2003 – PTH control in CKD.
3. Bell et al., 2014 – Longitudinal BMD changes in dialysis. Stein MS et al. BMD in dialysis patients.
4. Sit D et al. Bone markers and BMD correlation in HD.
5. Jeong JU et al. Nutritional markers and BMD in peritoneal dialysis.